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http://dx.doi.org/10.1016/j.ajic.2014.08.018Background: Intravenous needleless connectors (NCs) with a desired patient safety design may facilitate
effective intravenous line care and reduce the risk for central lineeassociated bloodstream infection
(CLA-BSI). We conducted a meta-analysis to determine the risk for CLA-BSI associated with the use of a
new NC with an improved engineering design.
Methods: We reviewed MEDLINE, Cochrane Database of Systematic Reviews, Embase, ClinicalTrials.gov,
and studies presented in 2010-2012 at infection control and infectious diseases meetings. Studies
reporting the CLA-BSIs in patients using the positive-displacement NC (study NC) compared with
negative- or neutral-displacement NCs were analyzed. We estimated the relative risk of CLA-BSIs with
the study NC for the pooled effect using the random effects method.
Results: Seven studies met the inclusion criteria: 4 were conducted in intensive care units, 1 in a home
health setting, and 2 in long-term acute care settings. In the comparator period, total central venous line
(CL) days were 111,255; the CLA-BSI rate was 1.5 events per 1,000 CL days. In the study NC period, total CL
days were 95,383; the CLA-BSI rate was 0.5 events per 1,000 CL days. The pooled CLA-BSI relative risk
associated with the study NC was 0.37 (95% conﬁdence interval, 0.16-0.90).
Conclusion: The NC with an improved engineering design is associated with lower CLA-BSI risk.
Copyright  2014 by the Association for Professionals in Infection Control and Epidemiology, Inc.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).Health care workers (HCWs) risk accidental needlestick injuries
and potential infection with bloodborne pathogens (BBPs) such as
hepatitis B or C viruses or HIV when they use needles in conjunc-
tion with intravenous (IV) therapy. With the emergence of HIVDirector, Scientiﬁc Research/
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mons.org/licenses/by-nc-nd/3.0/)infections and AIDS in the 1980s, HCWs, their unions, and U.S.
federal and state agencies that regulate occupational safety and
health became concerned about the potential risk of BBP infection
among HCWs. As a result, in 1992, the U.S. Occupational Safety and
Health Administration recommended that health care facilities use
engineering controls to help protect HCWs from these pathogens.
The use of such controls, including IV needleless connector (NC)
systems, when applicable, became mandatory under the Needle-
stick Safety and Prevention Act in 2001. The NCs that we see today
evolved from the industry’s initial efforts to make devices that
comply with these Occupational Safety and Health Administration
regulations. They were primarily designed for HCW safety, to pre-
vent accidental needlestick injuries and BBP infections. With the
initial introduction of split septum NCs, outbreaks of central linee
associated bloodstream infections (CLA-BSIs) occurred.1 With the
re-emphasis on the importance of infection control practices with
these devices (eg, septum disinfection, cap changes, etc), infectionl and Epidemiology, Inc. Published by Elsevier Inc. This is an open access article
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such devices, negative displacement mechanical NCs were intro-
duced. Then, to reduce the risk of CLA-BSIs and IV line occlusions,
positive-displacement NCs were introduced. This led to a number
of CLA-BSI outbreaks associated with some of these NCs.2-5 Ulti-
mately, this led to the Food and Drug Administration (FDA)
requesting that U.S. manufacturers of positive-displacement NCs
provide data that their devices were associated with risk of CLA-BSI
at or below the level associated with negative-displacement NCs.
Newer generations of NCs have been designed with the intention
of improving patient safety, speciﬁcally, reducingCLA-BSI risks. These
design features include the following: a visible ﬂuid path so that cli-
nicians can assess the efﬁcacy of their ﬂush technique; a solid, ﬂat,
smooth access surface that can be effectively disinfected; a 1-part
activation of the ﬂuid path for effective ﬂush; an open ﬂuid
pathway to provide a high ﬂow rate and avoid hemolysis; and other
desired safety features (eg, tight septum seal, minimal internal
complexity, ability to ﬂush with saline alone).6-8 In spite of the
improved design, there has been no systemic analysis on its associ-
ated CLA-BSI risk. We conducted an integrative review of the litera-
ture and meta-analysis to determine the risk of CLA-BSIs associated
with the use of the new NC.
METHODS
Data sources
We developed research protocol and data collection tools consis-
tentwith the recommendations per the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses.9 We searched the MEDLINE
database for relevant studiespublished from January2006-December
2012. We also searched ClinicalTrials.gov, Embase, and the Cochrane
Database of Systematic Reviews. Because the study NCwas relatively
new and published studies were scant, we extended the scope of the
search to include published abstracts from a comprehensive list of
major relevant infection control, infusion therapy, and infectious
diseases scientiﬁc meetingswhere early data could be presented and
identiﬁed.We performed Internet searches to locate relevant studies
presented at the following research meetings (2010-2012): Associa-
tion for Professionals in Infection Control and Epidemiology, Associ-
ation for Vascular Access, Interscience Conference on Antimicrobial
Agents and Chemotherapy, Infectious Disease Society of America,
InfusionNursesSociety,NationalHomeInfusionAssociation,TheFifth
Decennial International Conference on Healthcare-Associated In-
fections, and Society for Healthcare Epidemiology of America.
Study selections and data extraction
Study inclusion criteria were randomized controlled trials or
observational studies that reported the CLA-BSI rate inpatientswith
the newMaxPlus positive-displacement connector (CareFusion, San
Diego, CA) (study NC) compared with negative- or neutral-
displacement NCs. We used the following Medical Subject Head-
ings and key words: “bloodstream (infection OR infections) AND
(needleless connector) OR (mechanical valve) OR (needleless valve) OR
(venous access)” for the search. An Internet search was conducted
independently by 2 investigators. All abstracts identiﬁed were read
independently by 2 investigators (1 with a PhD, 1 with an MD).
Disagreement was resolved by discussions with a third investigator.
Datawere extracted on standardized forms on study design, setting,
patient population, facility location, number of CLA-BSIs (numer-
ator), and number of central venous line (CL) days (denominator)
during the studyNCdevice versus comparator device periods for the
studies included.We recordedCLA-BSI incidence density (infections
per 1,000 CL days) at each site. We contacted authors to obtain thenumerators and denominators when the study only reported the
summary CLA-BSI rates.
Additional data regarding IV line care practices and the case mix
index
To further evaluate potential risk factors associated with CLA-
BSI, we contacted authors to obtain IV management and disinfec-
tion practices related to CLs during the study NC and comparator
periods. These variables included use of a dedicated IV team, blood
draws through the connector attached to the CL, type of disinfec-
tants used in the cleaning of the NC, type of skin antiseptic used for
CL placement and maintenance, maximum sterile barrier precau-
tion usage, catheter securement method, and use of stopcocks in
the line. Finally, we obtained the case mix index (CMI) from the
Centers for Medicare and Medicaid Services as an aggregated
measure of patient disease severity for each study site.10-12
Statistical analysis
Using the aggregatedCLA-BSI rates during the comparators versus
the study NC periods, we estimated the relative risk (RR) for CLA-BSIs
associated with the study NC for each study. Then, we estimated the
pooled effect using the random effects method.13 For sensitivity
analysis, we ﬁt a random effect Poisson model with WinBUGS soft-
ware (Cambridge Institute of Public Health, Cambridge, UK) for the
pooled effect.14 We further tested the impact of the time trend co-
variate on the RR estimate of the study NC. The Poisson model does
not require normal distribution approximation for the effect of each
study. It also applies when the number of events for a study is zero.15
We used the Centers for Disease Control and Prevention’s (CDC)
Healthcare Infection Control Practices Advisory Committee reviewby
Lee and Umscheid16 and the U.S. FDA recommended methods17 to
compute a noninferioritymargin allowing comparison against both a
relative risk of 1.0 and a noninferiority margin.
We examined the distribution of the use of dedicated IV teams,
blood draws in the line, choice of NC disinfectants, skin antiseptics
used during CL insertion, use of maximum barrier precautions,
methods of catheter securement, and use of stopcocks in the lines at
each site. We examined whether any of these factors would inﬂu-
ence the risk of CLA-BSI associated with the study NC, using the
Poisson regression method.
Evaluation of heterogeneity across studies
To address the issue of potential heterogeneity and its impact on
the estimate, we conducted systemic analyses.9,18 We assessed het-
erogeneity between studies for the outcome using the Cochran Q
statistic,19 with P  .10 indicating signiﬁcant heterogeneity,20 and I2,
with suggested thresholds for low (25%-49%), moderate (50%-74%),
and high (>75%) values.21,22We generated a funnel plot to determine
study bias.23-25 A funnel plot is a graph of the study effect (log scale of
RR) plotted on the horizontal axis and a measure of within-study
variance (standard error of log RR) on an inverted vertical axis.26
We also estimated the pooled effect by splitting 1 aggregated
study27 into 5 individual study sites because each site was
geographically separate and consisted of independent patient pop-
ulations and potentially different clinical practices.
RESULTS
Data synthesis
Published studies
A ﬂow diagram outlining the search strategy and study selection
for MEDLINE is shown in Figure 1A. Our search strategies produced
Fig 1. (A) Flowchart of published study selection from MEDLINE. (B) Flowchart of studies presented at infection control, infusion therapy, and infectious diseases scientiﬁc meetings.
BSI, bloodstream infection; NC, needleless connector; CVC, central venous catheter.
Table 1
Descriptions of studies included in the meta-analysis
Variable Data
General information
Study lead author, principal investigator,
or presenter
Costello30 Taft31 Cain32 Gould33 Steininger34 Chernecky35 Lange27
Year of publication or presentation 2008 2009 2010 2010 2010 2011 2011
Where was the study published or presented
(journal, conference name)
Pediatrics INS NHIA AVA ICHAI SHEA SHEA
Hospital geographic region Northeast West Midwest Midwest West Northeast West
Hospital ICU bed size 24 26 NA 25 51 Unknown NA
Study design Retrospective Retrospective Retrospective Retrospective Prospective Prospective Retrospective
Study population Pediatric CICU NICU level 3 Home health ICU ALTAC MICU ALTAC
Preperiod information
Device name CLEARLINK Clave Clave Clave MicroClave Study NC V-LINK
Device mechanism (positive, negative,
neutral, etc)
Negative Negative Negative Negative Neutral Positive Negative
Data collection, start and end date (mm/yy) 01/05-03/06 01/04-10/06 04/08-05/09 1/08-12/08 01/07-12/07 02/09-08/09 01/09-10/09
Postperiod information
Device name Study NC Study NC Study NC Study NC Study NC InVision-Plus Study NC
Device mechanism (positive, negative,
neutral, etc)
Positive Positive Positive Positive Positive Neutral Positive
Data collection, start and end date (mm/yy) 04/06-12/06 11/06-12/08 06/09-03/10 01/09-03/10 04/08-04/09 02/10-08/10 11/9-08/10
ALTAC, adult long-term acute care; AVA, Association for Vascular Access; CICU, cardiac intensive care unit; ICHAI, International Conference of Healthcare Associated Infection;
ICU, intensive care unit; INS, Infusion Nurses Society; MICU, medical intensive care unit; NA, not applicable; NC, needleless connector; NHIA, National Home Infusion Asso-
ciation; NICU, neonatal intensive care unit; SHEA, Society for Healthcare Epidemiology of America; Unknown, study author declined to provide hospital identity.
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with NCs, all of which used a pretest versus posttest design. Among
them, 5 did not involve the study NC2-5,28; 1 involved an earlier
version versus a later version of the study NC device29; and only 1
involved a negative-displacement NC versus the study NC,30 which
was included in our meta-analysis. We did not ﬁnd any randomized
controlled trials or other observational studies that involved the
study NC in other published study databases or registries.
Studies presented at infection control, infusion therapy, and
infectious diseases scientiﬁc meetings
A ﬂow diagram showing the search strategies for studies pre-
sented at professional meetings is shown in Figure 1B. Our search
strategies produced an additional 6 citations27,31-35 from 10 obser-
vational studysites thatmet the searchcriteria.Weexcluded3studies
involving the study NC: 2 used another positive-displacement NC asthe comparator36,37 and 1 used mixed NC devices as comparators.38
All 3 excluded studies reported outcomes favoring the study NC.
Descriptive statistics
All 7 observational studies that met the inclusion criteria used a
pretest versus posttest design (Table 1). All studies used the CDC’s
National Healthcare Safety Network CLA-BSI deﬁnition for outcome
measure. Six studies used a negative- or neutral-displacement NC
as the comparator device during the pretest period and the study
NC as the test device during the posttest period. One study used the
study NC as the pretest device and a neutral NC as the posttest
device. Four studies were conducted in intensive care units, 1 in a
home health setting, and 2 in long-term acute care settings.
In the comparator period, the total number of CL days was
111,255 (range, 2,605-61,816), and the overall weighted CLA-BSI
rate was 1.5 events per 1,000 CL days (range, 0.18-5.73 events per
Table 2
Summary of study results included in the meta-analysis
Study lead author, principal
investigator, or presenter
Comparators Study NC
Number of
CL days
Number of
CLA-BSI events
CLA-BSI rate
(per 1,000 CL days)
Number of
CL days
Number of
CLA-BSI events
CLA-BSI rate
(per 1,000 CL days)
Costello30 5,234 30 5.73 3,675 11 2.99
Taft31 4,123 17 4.12 2,838 4 1.41
Cain32 61,816 11 0.18 50,148 2 0.04
Gould33 5,391 22 4.08 6,011 0 0
Steininger34 8,947 20 2.24 6,930 8 1.15
Chernecky35 2,605 4 1.54 2,766 12 4.34
Lange27 23,139 66 2.85 23,015 11 0.48
Sum 111,255 170 1.5 95,383 48 0.5
CL, central venous line; CLABSI, central lineeassociated bloodstream infection; NC, needleless connector.
Fig 2. Relative risk and 95% conﬁdence intervals of the study needleless connector
versus comparators. CLABSI, central lineeassociated bloodstream infection.
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was 95,383 (range, 2,766-50,148), and the overall weighted CLA-BSI
rate was 0.5 events per 1,000 CL days (range, 0-4.34 events per
1,000 CL days) (Table 2).
RR estimate
The estimatedRRof CLA-BSIs associatedwith the studyNC ranged
from 0.02-2.83 across the 7 studies. The pooled random effect
method showed a 63% CLA-BSI risk reduction associated with the
studyNC (RR, 0.37;95%conﬁdence interval [CI], 0.16-0.90) (Fig2). The
sensitivity analysis using a random effect Poisson model showed a
69% CLA-BSI risk reduction associated with the study NC (RR, 0.31;
95% CI, 0.19-0.47). The model including time trend as a covariate
yielded a slightly larger estimate (RR, 0.43; 95% CI, 0.29-0.69).
Heterogeneity analysis
Analysis revealed signiﬁcant heterogeneity between studies
(I2 ¼ 75.5%, P ¼ .0004) (Table 3). This heterogeneity was largely
explained by the outlying study of Chernecky et al.35 The funnel plot
illustrated the potential bias of this study (Fig 3A). When the study
by Chernecky et al was removed from the analysis, the heteroge-
neity index reduced from high (I2 ¼ 75.5%, P ¼ .0004) to moderate
(I2¼ 54.9%, P¼ .026), with a RR of 0.28 (95% CI, 0.13-0.60).When the
studies by Gould et al33 and Chernecky et al35 were both removed,
the I2 was reduced to 46.0% (P ¼ .11), indicating low heterogeneity
with a slight change of the RR of 0.33 (95% CI, 0.16-0.66).
When we split one aggregated study27 into 5 individual study
sites, the pooled risk reduction was slightly more favorable to the
study NC (random effect model: RR, 0.30; 95% CI, 0.15-0.59). The
heterogeneity analysis produced consistent and slightly morefavorable results associated with the study NC compared with
treating 5 sites in the Lange study as a single aggregated site
(Table 3 and Fig 3B).
Analysis of seasonality, CMI, and IV line care practice
Across all the studies there was a total of 194 months covered.
Only 7 months failed to overlap. Hence, the seasons were well
balanced in the study NC and comparator periods. Our analysis on
the CMI showed very similar patient severity during the study NC
and comparator periods. The site-speciﬁc IV line care and cleaning
practices were virtually identical across the study NC and
comparator periods. Detailed appendices with supplemental in-
formation are available on request.
DISCUSSION
Desired engineering design of the NCs
Our meta-analysis demonstrated that the study NC with
improved engineering design features that facilitate effective dis-
infections was associated with a lower risk of CLA-BSI. In the
continuing evolution of the NCs, many have become complex in
design. The complexities might have made some NCs harder to
disinfect, ﬂush completely, or use correctly, all of which could
contribute to CLA-BSI risk. In contrast, the design of the study NC
has 8 of the 9 desired features outlined by infection prevention
experts,6 including a solid, smooth external septum surface; a tight
septum housing seal; a clear ﬂuid pathway; minimal internal
complexity; reduction or elimination of interstitial or dead space;
elimination of a speciﬁc disinfection-clamping sequence; a straight
ﬂuid pathway; no blood reﬂux; and the ability to ﬂush with saline
alone. These desired features might explain, in part, the lower CLA-
BSI rates seen in our meta-analysis. The favorable results also are
supported by previous in vitro studies. For example, the study NC
was found to be the second best NC in low colony forming units
(CFU) among all devices tested.39 Another in vitro study also
demonstrated a smaller number of Staphylococcus aureus (CFU/mL)
detected in saline collected after passing through various NCs.40
These favorable results may have been related to the NC design,
which may have inﬂuenced the efﬁcacy of the decontamination
and disinfection process.
Our study revealed that the study NC, a new generation of NCs
with improved patient safety design, was associated with reduced
CLA-BSI risk. Previously, the study NC was not implicated in any
published studies that showed increased CLA-BSI risk associated
with positive-displacement NCs.2-5,28 The only published study
involving the study NC is from Boston’s Children’s Hospital, which
demonstrated a reduced CLA-BSI rate associated with using the
study NC.30 Unfortunately, that study was not cited in the review by
Lee and Umscheid16 that was presented to the CDC’s Healthcare
Table 3
Relative risk and heterogeneity analysis
Study inclusion and exclusion
Pooled relative risk (95% conﬁdence interval)
s2
Q statistic-c2 I2 ¼ (Qdf)/Q
Poisson
model
Fixed-effect
model
Random-effect
model Value df P value
I2 value
(%)
Heterogeneity
category
Lange’s study treated as a single aggregated site
All studies (n ¼ 7) 0.31 (0.19-0.47) 0.38 (0.27-0.54) 0.37 (0.16-0.90) 0.82 24.4 6 .0004 75.5 High
Removing Chernecky (n ¼ 6) 0.25 (0.17-0.36) 0.31 (0.21-0.44) 0.28 (0.13-0.60) 0.56 11.1 5 .0257 54.9 Moderate
Removing Chernecky and Gould (n ¼ 5) 0.30 (0.20-0.42) 0.32 (0.22-0.47) 0.33 (0.16-0.66) 0.40 7.41 4 .1156 46.0 Low
Lange’s study treated as 5 independent sites
All sites (n ¼ 11) 0.32 (0.23-0.43) 0.40 (0.28-0.56) 0.30 (0.15-0.59) 0.84 26.22 10 .0035 61.9 Moderate
Removing Chernecky (n ¼ 10) 0.25 (0.17-0.35) 0.32 (0.22-0.47) 0.23 (0.11-0.47) 0.43 14.12 9 .1180 36.3 Low
Removing Chernecky and Gould (n ¼ 9) 0.29 (0.20-0.42) 0.34 (0.23-0.49) 0.26 (0.12-0.54) 0.26 9.95 8 .2689 19.6 Low
Fig 3. (A) Funnel chart: Lange’s study treated as a single aggregated site. (B) Funnel
chart: Lange’s study treated as 5 independent sites. RR, relative risk.
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basis of the 2011 CDC’s IV guideline recommendations related to
NCs. In July 2010, the FDA requested postmarketing surveillance
data from manufacturers of positive-displacement NCs under Sec-
tion 522 of the Federal Food and Drug Act. Because it was consid-
ered possible that this was a class effect for positive-displacement
NCs, all positive-displacement NCs on the U.S. market were
included in the request, despite the fact that the study NC showed
favorable results in the published study.30 Our analysis of the study
NC suggests that CLA-BSI rates associated with positive-
displacement NCs may not be a class effect. It might be that thespeciﬁc design features of individual devices may facilitate or
hinder effective disinfection and IV line care, which may in turn be
associated with higher or lower CLA-BSI risk.6
Our study found that 5 out of 6 recent studies presented at
infection control, infusion therapy, and infectious diseases research
meetings demonstrated that the study NC was associated with
lower CLA-BSI risk.27,31-34 These studies encompass pediatric,
neonatal, and adult intensive care units; home health care settings;
and long-term acute care settings with >200,000 CL days.
Of the 3 studies excluded from our meta-analysis because
another positive-displacement or mixed device was used as a
comparator,36-38 all showed results favoring the study NC. The
fourth study reported sustained zero CLA-BSI cases for 17 consec-
utive months in the study NC period.29
The only study that found anunfavorable association of the study
NC and CLA-BSI rate was the one by Chernecky et al.35 This study
was a multicenter comparison of bloodstream infection rates
associated with use of the split septum, positive or negative pres-
sure mechanical valves to a zero ﬂuid displacement connector. Only
a single facility out of 6 facilities in the Chernecky study involved
using the current study NC as the comparator. As can be seen in data
Table 2, the total number of CLA-BSI events in the Chernecky study
throughout the entire study period (14months)was relatively small
(n¼ 16). Because of its small sample size, its inﬂuence on the pooled
RR estimate was minor despite its signiﬁcant inﬂuence on hetero-
geneity. In addition, the result from this single facility in Cher-
necky’s observational study was not consistent with the results
from her previous in vitro study39 that compared 5 different NCs, in
which the current study NC ranked second best in terms of CFUs.
Furthermore, there was no signiﬁcant difference in mean CFUs be-
tween the study NC and the leading device.
All studies included in our meta-analysis were quasi-
experimental pre-post designs. This design presumes no time
trend across the preperiod and postperiod. When we adjusted for
the time trend, this covariate showed a RR of 0.71 (95% CI,
0.50-0.97), indicating a signiﬁcant decline of CLA-BSI over time,
consistent with the nationwide trend.41 Nevertheless, even after
adjusting for the effect of the time trend, the RR for CLA-BSIs
associated with the study NC was still signiﬁcantly lower than the
comparators (RR, 0.43; 95% CI, 0.29-0.69).IV line care, NC disinfection practice, and inﬂuence of the CMI
The use of various preventive measures that were implemented
as part of the CLA-BSI prevention insertion bundle, including
maximum barrier precautions (ie, full drapes, gowns, masks,
gloves), hand hygiene, and chlorhexidine with alcohol for skin
antisepsis, together with strict adherence to aseptic precautions
and vigilant management of the catheter and exit site, might also
have contributed to the decrease in CLA-BSI density. Nevertheless,
Y.P. Tabak et al. / American Journal of Infection Control 42 (2014) 1278-84 1283from the data collected through our follow-up with the authors,
nearly identical IV line and NC care and cleaning practice were used
during both the study NC and comparator periods. The single
discordant pair occurred in the Taft study,31 where blood draws in
the line, which could increase CLA-BSI risk, were allowed during
the study NC period. However, the CLA-BSI rate fell during the
study NC period. Hence, the reduced CLA-BSI risk associated with
study NC use appears independent of IV line care and NC disin-
fection practices.
TheCMI takes intoaccount the relativenumbersofvarious typesof
patients being treated as categorized by diagnosis-related groups.10 It
is an aggregated measure of patient composition and severity of
illness being cared for at the health care site level. It is a system for
classifyingpatient severityof illnessbasedonprincipal andsecondary
diagnoses, demographic variables, hospital procedures performed,
and the interaction of these factors. Our analysis showed very similar
CMIs during the study NC and comparator periods. Hence, the
reduced CLA-BSI risk associated with the study NC use appears in-
dependent of severity of illness of the patient population.
Study limitations
Given that the study NC is a relatively new device, we were only
able to ﬁnd 7 studies; most of them were abstracts presented in
infection control, infusion therapy, and infectious diseases scientiﬁc
research meetings. Because of limited publications, we expanded
our search to abstracts presented at research meetings for more
current studies. Including grey literature, such as abstracts pre-
sented in research meetings for meta-analysis, may inﬂuence the
meta-analysis results, but their inclusion is gaining acceptance.42
Some experts even recommend in favor of its use43 because not
including such literature could represent a potential form of
underreporting bias, especially for studies that fail toﬁnd signiﬁcant
differences.44 Although reasonable concerns over the quality of
unpublished studies are warranted, some studies suggest similar
quality in published and unpublished studies.45 Furthermore, there
is a good correlation between effect estimates when the grey liter-
ature is included.46 In part, this may be because the most common
source are abstracts, whichmost often do receive some form of peer
review prior to acceptance. None of the studies in themeta-analysis
were funded by the manufacturer of the study NC, and none of the
authors of the studies included in the meta-analysis were em-
ployees of the study NC manufacturer.
We contacted study authors to gather additional information on
antiseptic practices and central line protocols to assess potential
confounding factors during the study NC versus comparator pe-
riods. Because these data were collected poststudy, there might be
recall bias. To minimize the potential recall bias, we sent authors a
concise data collection form and received completed responses
from all but 1 author regarding the clinical practice during their
study periods.
CONCLUSION
A NC with improved engineering design that facilitates effective
IV line care is associated with lower CLA-BSI risk. Because of the
limited number of publications, the current meta-analysis was
expanded to studies presented in scientiﬁc research meetings.
Additional publications in the future should continue to shed light
in this area.
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